Nov 29 (Reuters) - Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA). (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | -1.79% | -11.65% | -82.32% |
May. 14 | Transcript : Vivos Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.32% | 6.68M | |
+72.98% | 12.38B | |
-20.40% | 7.81B | |
+6.24% | 6.72B | |
+12.78% | 5.39B | |
+38.73% | 5.03B | |
-16.79% | 4.72B | |
-25.33% | 4.06B | |
-29.57% | 2.68B | |
+52.38% | 2.59B |
- Stock Market
- Equities
- VVOS Stock
- News Vivos Therapeutics, Inc.
- US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea